论文部分内容阅读
贫血是多发性骨髓瘤的常见并发症。在多发性骨髓瘤的早期,如经化疗可诱导病情完全缓解,贫血可以得到纠正,但如果疾病持续进展,可导致严重症状性贫血,并常需输血治疗。作者报道重组人红细胞生成素治疗多发性骨髓瘤相关贫血的经验。 13例患者,皮下注射重组人红细胞生成素,每周3次,持续6个月。开始每次剂量为15单位/kg,如3周内无反应,剂量增至20单位/kg,若3周内仍无反应,再加量至50单位/kg。如有效应则逐渐减量,使血红蛋白维持在7.4～8.7 mmol/L(12～14 g/dl)。
Anemia is a common complication of multiple myeloma. In the early stage of multiple myeloma, if chemotherapy can induce a complete remission of the disease, anemia can be corrected, but if the disease continues to progress, it can lead to severe symptomatic anemia and often require transfusion therapy. The authors report the experience with recombinant human erythropoietin in treating multiple myeloma-related anemia. Thirteen patients were injected subcutaneously with recombinant human erythropoietin three times weekly for 6 months. The initial dose of 15 units / kg, such as 3 weeks no response, the dose increased to 20 units / kg, if 3 weeks still no response, plus the amount of 50 units / kg. If the effect is tapering, hemoglobin maintained at 7.4 ~ 8.7 mmol / L (12 ~ 14 g / dl).